These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
611 related articles for article (PubMed ID: 30957314)
1. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease. Geraghty NJ; Watson D; Sluyter R Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314 [TBL] [Abstract][Full Text] [Related]
2. The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease. Geraghty NJ; Belfiore L; Ly D; Adhikary SR; Fuller SJ; Varikatt W; Sanderson-Smith ML; Sluyter V; Alexander SI; Sluyter R; Watson D Clin Exp Immunol; 2017 Oct; 190(1):79-95. PubMed ID: 28665482 [TBL] [Abstract][Full Text] [Related]
4. The adenosine generating enzymes CD39/CD73 control microglial processes ramification in the mouse brain. Matyash M; Zabiegalov O; Wendt S; Matyash V; Kettenmann H PLoS One; 2017; 12(4):e0175012. PubMed ID: 28376099 [TBL] [Abstract][Full Text] [Related]
5. [Extracellular adenosine is a therapeutic target for limiting graft-versus-host disease and enhancing the graft-versus-tumor effect against hematopoietic malignancy]. Tsukamoto H Yakugaku Zasshi; 2014; 134(10):1021-7. PubMed ID: 25274211 [TBL] [Abstract][Full Text] [Related]
6. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420 [TBL] [Abstract][Full Text] [Related]
7. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice. Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240 [TBL] [Abstract][Full Text] [Related]
8. Elevated CD39+T-Regulatory Cells and Reduced Levels of Adenosine Indicate a Role for Tolerogenic Signals in the Progression from Moderate to Severe COVID-19. Elsaghir A; El-Sabaa EMW; Zahran AM; Mandour SA; Salama EH; Aboulfotuh S; El-Morshedy RM; Tocci S; Mandour AM; Ali WE; Abdel-Wahid L; Sayed IM; El-Mokhtar MA Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139439 [TBL] [Abstract][Full Text] [Related]
9. A single-nucleotide polymorphism in the human ENTPD1 gene encoding CD39 is associated with worsened graft-versus-host disease in a humanized mouse model. Adhikary SR; Cuthbertson P; Turner RJ; Sluyter R; Watson D Immunol Cell Biol; 2020 May; 98(5):397-410. PubMed ID: 32181525 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716 [TBL] [Abstract][Full Text] [Related]
11. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. Schuler PJ; Saze Z; Hong CS; Muller L; Gillespie DG; Cheng D; Harasymczuk M; Mandapathil M; Lang S; Jackson EK; Whiteside TL Clin Exp Immunol; 2014 Aug; 177(2):531-43. PubMed ID: 24749746 [TBL] [Abstract][Full Text] [Related]
12. Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis. Beldi G; Wu Y; Banz Y; Nowak M; Miller L; Enjyoji K; Haschemi A; Yegutkin GG; Candinas D; Exley M; Robson SC Hepatology; 2008 Sep; 48(3):841-52. PubMed ID: 18752325 [TBL] [Abstract][Full Text] [Related]
14. The role of the CD39-CD73-adenosine pathway in liver disease. Wang S; Gao S; Zhou D; Qian X; Luan J; Lv X J Cell Physiol; 2021 Feb; 236(2):851-862. PubMed ID: 32648591 [TBL] [Abstract][Full Text] [Related]
15. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125 [TBL] [Abstract][Full Text] [Related]
16. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells. Romio M; Reinbeck B; Bongardt S; Hüls S; Burghoff S; Schrader J Am J Physiol Cell Physiol; 2011 Aug; 301(2):C530-9. PubMed ID: 21593451 [TBL] [Abstract][Full Text] [Related]
17. Long-term treatment with the P2X7 receptor antagonist Brilliant Blue G reduces liver inflammation in a humanized mouse model of graft-versus-host disease. Geraghty NJ; Watson D; Sluyter R Cell Immunol; 2019 Feb; 336():12-19. PubMed ID: 30545568 [TBL] [Abstract][Full Text] [Related]
18. Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73 Ahmadi P; Hartjen P; Kohsar M; Kummer S; Schmiedel S; Bockmann JH; Fathi A; Huber S; Haag F; Schulze Zur Wiesch J Cells; 2020 Jul; 9(8):. PubMed ID: 32707842 [TBL] [Abstract][Full Text] [Related]
19. Alterations in CD39/CD73 axis of T cells associated with COVID-19 severity. Dorneles GP; Teixeira PC; da Silva IM; Schipper LL; Santana Filho PC; Rodrigues Junior LC; Bonorino C; Peres A; Fonseca SG; Monteiro MC; Boeck CR; Eller S; Oliveira TF; Wendland EM; Romão PRT J Cell Physiol; 2022 Aug; 237(8):3394-3407. PubMed ID: 35754396 [TBL] [Abstract][Full Text] [Related]
20. CD73 controls ocular adenosine levels and protects retina from light-induced phototoxicity. Losenkova K; Takeda A; Ragauskas S; Cerrada-Gimenez M; Vähätupa M; Kaja S; Paul ML; Schmies CC; Rolshoven G; Müller CE; Sandholm J; Jalkanen S; Kalesnykas G; Yegutkin GG Cell Mol Life Sci; 2022 Feb; 79(3):152. PubMed ID: 35212809 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]